Medical imaging is a complex field that involves various technologies, each with its unique strengths and limitations. Recently, French startup Gleamer has made headlines by acquiring two AI-powered MRI analysis startups, Pixyl and Caerus Medical. This move suggests that Gleamer aims to leverage existing research and development to tackle the challenging task of creating AI-powered MRI solutions.Gleamer's decision to acquire rather than start from scratch is a pragmatic approach. By building upon the work already done by Pixyl and Caerus Medical, the company can accelerate its progress and minimize the risks associated with developing new technologies from scratch. However, this also raises questions about the intellectual property rights and potential conflicts of interest involved in such acquisitions.The development of AI-powered MRI analysis is a highly regulated field that requires careful consideration of ethical and safety implications. As the technology advances, it is essential to address the technical challenges and ensure that any solutions are safe for patient use. The future of medical imaging will depend on the responsible and innovative use of AI technologies.